期刊文献+

影响华法林抗凝血作用的有关因素 被引量:102

Related factors affecting anticoagulant effect of warfarin
原文传递
导出
摘要 华法林为口服抗凝血药,用于治疗和预防血栓栓塞性疾病。华法林抗凝血作用(增强或减弱)受多种因素影响。这些因素包括遗传、疾病、药物、草药以及食物等。CYP2C9多态性(主要为CYP2C9*2、CYP2C9*3)、肝功能低下、甲状腺功能亢进、心力衰竭以及阿司匹林、氯吡格雷、咪康唑、当归、茴香、芹菜、菠萝、洋葱、大蒜等和华法林的相互作用均能致华法林抗凝血作用增强。而VKORC1的基因突变以及利福平、卡马西平、人参、绿茶,富含维生素K的制剂或饮食等和华法林相互作用均能使华法林抗凝血作用减弱。另外,有些药物如:苯妥英钠,既能增强又能减弱华法林的抗凝血作用。了解这些因素对华法林抗凝血作用的影响,定期监测INR值,进行个体化给药,有利于华法林安全有效应用。 Warfarin is an oral anticoagulant used in the treatment and prophylaxis ofthromboembolic disorders. Many factors affect warfarin's anticoagulant effect (enhancement or diminishment). These factors include genetics, diseases, drugs, herbal medicines, food, etc. Several polymorphisms of CYP2C9 (mainly CYP2C9*2 and CYP2C9*3), liver function insufficiency, hyperthyroidism, heart failure, and interactions of warfarin with aspirin, clopidogrel, miconazole, angelica, fennel, celery, pineapple, onion, and garlic enhance the anticoagulant effect of warfarin. Gene mutation of VKORC1 and interactions of warfarin with rifampicin, carbamazepine, ginseng, green tea, and plenty vitamin K-containing preparations or diets diminish the anticoagulant effect of warfarin. Further more, some drugs such as phenytoin sodium can increase as well as decrease warfarin's anticoagulant effect. Understanding of these factors affecting the anticoagulant effect of warfarin, regular monitoring oflNR, and individualizing medication are beneficial to safe and effective use of warfarin.
作者 郑策 梅丹
出处 《药物不良反应杂志》 2007年第4期256-261,共6页 Adverse Drug Reactions Journal
关键词 华法林 抗凝作用 相关因素 warfarin anticoagulant effect related factors
  • 相关文献

参考文献27

  • 1Ansell J,Hirsh J,Poller L,et al.The pharmacology and management of the vitamin K antagonists:the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy[J].Chest,2004,126(3 Suppl):204s-233s.
  • 2Miners JO,Birkett DJ.Cytochrome P4502C9:an enzyme of major importance in human drug metabolism[J].Br J Clin Pharmacol,1998,45(6):525-538.
  • 3Scordo MG,Pengo V,Spina E,et al.Influence of CYP2C9 and CYP2C19 genetic polymorphisms on warfarin maintenance dose and metabolic clearance[J].Clin Pharmacol Ther,2002,72(6):702-710.
  • 4Palkimas MP,Skinner HM,Gandhi PJ,et al.Polymorphism induced sensitivity to warfarin:a review of the literature[J].J Thromb Thrombolysis,2003,15(3):205-212.
  • 5Furuya H,Fernandez-Salguero P,Gregory W,et al.Gennetic polymorphism of CYP2C9 and its effect on warfarin maintenance dose requirement in patients undergoing anticoagulation therapy[J].Pharmacogenetics,1995,5(6):389-392.
  • 6Aithal GP,Day CP,Kesteven PJ,et al.Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarindose requirement and risk of bleeding complications[J].Lancet,1999,353(9154):717-719.
  • 7Higashi MK,Veenstra DL,Kondo LM,et al.Association between CYP2C9 genetic variants and antcoagula tionrelated outcomes during warfarin therapy[J].JAMA,MA,2002,287(13):1690-1698.
  • 8Leung AY,Chow HC,Kwong YL,et al.Genetic polymorphism in exon 4 of cytochrome P450 CYP2C9 may be associated with warfarin sensitivity in Chinese patients[J].Blood,2001,98(8):2584-2587.
  • 9Rost S,Fregin A,Ivaskevicius V,et al.Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2[J].Nature,2004,427(6974):537-541.
  • 10Harrington DJ,Underwood S,Morse C,et al.Pharmacodynamic resistance to warfarin associated with a Va166Met substitution in vitamin K epoxide reductase complex subunit 1[J].Thromb Haemost,2005,93(1):23-26.

二级参考文献46

  • 1姚浩洁,赵志刚,代金玉.影响华法令药效的药物与食物[J].实用心脑肺血管病杂志,2006,14(3):216-216. 被引量:10
  • 2许俊堂.口服华法林INR的波动及其调节[J].中国医刊,2006,41(8):46-48. 被引量:10
  • 3杨扬,姚均迪,林晓耘.胺碘酮与华法林的相互作用[J].海军医学杂志,2006,27(3):269-271. 被引量:18
  • 4SPORTIF Ⅲ Investigators. Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF Ⅲ): randomized controlled trial [J] .Lancet, 2003, 362(9397):1691.
  • 5Halperin JL. Efficacy and safety study of oral direct thromnin inhibitor ximelagatran compared with dose-adjusted warfarin in the prevention of stroke and systemic embolic events in patients with atrial fibrillation:SPORTIF V [C] . American Heart Associat
  • 6Kalta L, Yu G, Perez I, et al. Prospective cohort study to determine if trial efficacy of anticoagulation for stroke prevention in atrial fibrillation translates into clinical effectiveness [J] .BMJ, 2000, 320(7244):1236.
  • 7Economides Munoz C, Singh BN. Antithrombotic Therapies for stroke prevention fibrillation [J] . Minerva Cardioangiol, 2004, 52(2):125.
  • 8Ferro JM. Atrial fibrillation and cardioembolic stroke [J] . Minerva Cardiangiol, 2004, 52(2):111.
  • 9Anderson M, Kirk M. Anticoagulation in atrial fibrillation [J] . MedHealthR. I. 2004, 87(4):98.
  • 10Hart RG, Boop BS, Anderson DC. Oral anticoagulants and intracranial hemorrhage: Facts and hypotheses [J] . Stroke, 1995, 26(8): 1471.

共引文献75

同被引文献735

引证文献102

二级引证文献510

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部